医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

KKR Partners with Radiant Life Care

2017年07月17日 PM09:30
このエントリーをはてなブックマークに追加


 

MUMBAI, India

Leading hospital management company Radiant Life Care (“Radiant” or the “Company”) and global investment firm KKR today announced the signing of a definitive agreement under which KKR will invest approximately US$200 million to acquire a 49% stake in Radiant. Working together, KKR, Radiant’s management team and the Company’s promoter, Abhay Soi, Chairman and Managing Director of Radiant, will expand the Company’s footprint across India to make high-quality health care services more accessible to customers across the country and from overseas.

This Smart News Release features multimedia. View the full release here: http://www.businesswire.com/news/home/20170717005551/en/

Radiant develops and operates high-end, state-of-the-art quaternary care facilities in India. The Company refurbishes hospitals and enhances their operations through initiatives such as the introduction of high-end specialty services, recruitment of experienced medical professionals, reengineering processes, capacity expansion and by modernizing facilities for improved care giving and patient experiences.

Radiant’s facilities include BLK Super Speciality Hospital (“BLK”) in New Delhi and the Nanavati Super Speciality Hospital in Mumbai, both of which have been rebuilt and re-launched since being acquired by the Company. Radiant is one of the few established companies managing hospitals in the leading metropolitan areas of Mumbai and Delhi that offer high-end quaternary care, including vital organ transplants. Its hospitals offer some of the largest bone marrow transplant units in the world.

KKR’s investment in Radiant continues the firms’ partnership, as KKR has previously extended financing to Radiant to support the Company’s growth. KKR makes the proposed investment from its KKR Asian Fund III.

Abhay Soi said, “As a student of finance, I once dreamt of working for KKR, and therefore partnering with them today is a watershed moment for me. KKR has been a long-term partner to Radiant and we are very excited to deepen our relationship with the firm, which shares our vision for health care excellence in India. KKR has more than two decades of experience investing in and working alongside health care companies, and with their expertise, we look forward to expanding our business. I welcome Sanjay and Nikhil on our board and the immense value they bring to us.”

Sanjay Nayar, Member of KKR and CEO of KKR India, said, “This is an exciting time for health care in India given the growing demand for superior medical treatment. In this industry, scale and operating leverage are increasingly important, and Radiant has a unique opportunity to acquire assets during a time of industry consolidation. KKR is focused on providing long-term capital solutions to experienced health care partners like the Radiant team to continue their work to deliver high-quality care and services.”

Nikhil Srivastava, Director at KKR, added, “We are impressed with the work of Abhay and his team in creating efficient and high-quality centers of medical care. Radiant has seen strong growth over the past five years. We look forward to supporting the next phase of growth and expansion.”

KKR has invested more than US$3 billion through its private equity practice in India since 2006. The firm is extensively engaged in the operations and strategies of its portfolio companies to provide resources and advice to accomplish shared goals. KKR’s private equity portfolio in India includes, but is not limited to, Aricent, Bharti Infratel, Avendus Capital, Cafe Coffee Day, Emerald Media, Magma Fincorp, Max Financial Services, and SBI Life. In addition to a strong private equity practice, KKR is highly focused on credit, capital markets and real estate opportunities in India.

About Radiant Life Care

Radiant is in the business of developing/redeveloping hospitals to provide high end quaternary care. Presently, Radiant has two iconic facilities in its portfolio namely: BLK Super Specialty Hospital, Delhi and Nanavati Super Specialty Hospital, Mumbai.

Radiant forayed into healthcare in 2010 with the re-development and commissioning of BLK, a 650-bed hospital, one of the largest private sector hospitals in Delhi and NCR. BLK is now being expanded into a 1600-bed quaternary care hospital. Besides this flagship hospital, Radiant collaborated with the Nanavati Hospital Trust in 2014 to take over the operations of Nanavati, a 350-bed multi-specialty hospital. Over the next four years, Radiant plans to transform Nanavati into a 1000 bed state-of-the-art quaternary care institute.

About KKR

KKR is a leading global investment firm that manages investments across multiple asset classes including private equity, energy, infrastructure, real estate, credit and hedge funds. KKR aims to generate attractive investment returns by following a patient and disciplined investment approach, employing world‐class people, and driving growth and value creation at the asset level. KKR invests its own capital alongside its partners’ capital and brings opportunities to others through its capital markets business. References to KKR’s investments may include the activities of its sponsored funds. For additional information about KKR & Co. L.P. (NYSE:KKR), please visit KKR’s website at www.kkr.com and on Twitter @KKR_Co.

View source version on businesswire.com: http://www.businesswire.com/news/home/20170717005551/en/

CONTACT

Media:
Radiant Life Care:
Parul
Chhabra, +91-98-1085-5410
parul.chhabra@blkhospital.com
or
KKR:
KKR
Asia Pacific:
Anita Davis, +852-3602-7335
Anita.Davis@kkr.com
or
KKR Americas:
Kristi
Huller / Cara Kleiman, +1-212-750-8300
Media@kkr.com
or
Edelman
(for KKR India)
Siddharth Panicker, +91-9820-857-522
siddharth.panicker@edelman.com

同じカテゴリーの記事 

  • Poxel to Report Its 2023 Annual Results by the End of April 2024
  • Kolmar Korea Wins Case Against Italian Cosmetics Maker Intercos for Suncare Technology Theft
  • 大手CDMOのPCIファーマ・サービシズが初の包括ESG報告書を発表
  • Aurion Biotech Announces First Canadian Subject Dosed in Phase 1 / 2 Clinical Trial
  • 领先的合同开发和制造组织PCI Pharma Services发布首份综合ESG报告